2 December 2024
Deltex Medical Group
plc
("Deltex
Medical" or the "Company")
Holding in
Company
Deltex Medical Group plc (AIM: DEMG)
was informed on 28 November 2024 that, as a result of a purchase on
7 October 2024 of 500,000 ordinary shares of 0.01 pence each in the
Company ("Ordinary
Shares"), Michael Stubbs' holding of Ordinary Shares
increased to 113,968,383 Ordinary Shares, representing
approximately 6.01 per cent of the Company's issued share capital.
The Company has also been informed that Michael Stubbs now
holds 122,238,383 Ordinary Shares, representing approximately 6.45% of the
Company's issued share capital.
For
further information, please contact:
|
Deltex Medical Group plc
|
01243 774 837
|
|
Nigel Keen, Chairman
|
investorinfo@Deltexmedical.com
|
|
Andy Mears, Chief
Executive
|
|
|
Natalie Wettler, Group Finance
Director
|
|
|
|
|
|
Allenby Capital Limited - Nominated Adviser &
Broker
|
020 3328 5656
|
|
Jeremy Porter / Vivek Bhardwaj
(Corporate Finance)
|
info@allenbycapital.com
|
|
Tony Quirke / Stefano Aquilino
(Sales & Corporate Broking)
|
|
Notes for
Editors
Deltex Medical's technology
Deltex Medical's TrueVue System uses
proprietary haemodynamic monitoring technology to assist clinicians
to improve outcomes for patients as well as increase throughput and
capacity for hospitals.
Deltex Medical has invested over the
long term to build a unique body of peer-reviewed, published
evidence from a substantial number of trials carried out around the
world. These studies demonstrate statistically significant
improvements in clinical outcomes providing benefits both to
patients and to the hospital systems by increasing patient
throughput and expanding hospital capacity.
The Group's flagship, world-leading,
ultrasound-based oesophageal Doppler monitoring ("ODM") is
supported by 24 randomised control trials conducted on
anaesthetised patients. As a result, the primary application for
ODM is focussed on guiding therapy for patients undergoing elective
surgery, although sedated patients in intensive care are still an
important part of our business. The Group's new, next generation
monitor makes the use of the ODM technology more intuitive and
provides augmented data on the status of each patient.
Deltex Medical's engineers and
scientists carried out successful research in conjunction with the
UK's National Physical Laboratory ("NPL"), which has enabled the
Group's 'gold standard' ODM technology to be extended and developed
so that it can be used completely non-invasively. This will
significantly expand the application of Deltex Medical's technology
to non-sedated patients. This new technological enhancement, which
will be released on the new next generation monitor, will
substantially increase the addressable market for the Group's
haemodynamic monitoring technologies and is complementary to the
long-established ODM evidence base.
Deltex Medical's new non-invasive
technology has potential applications for use in a number of
healthcare settings, including:
§ Accident
& Emergency for the rapid triage of patients, including the
detection and diagnosis of sepsis;
§ in general
wards to help facilitate a real-time, data-driven treatment regime
for patients whose condition might deteriorate rapidly;
and
§ in
critical care units to allow regular monitoring of patients
post-surgery who are no longer sedated or intubated.
One of the key opportunities for the
Group is positioning this new, non-invasive technology for use
throughout the hospital. Deltex Medical's haemodynamic monitoring
technologies provide clinicians with beat-to-beat real-time
information on a patient's circulating blood volume and heart
function. This information is critical to enable clinicians to
optimise both fluid and drug delivery to patients.
Deltex Medical's business model is
to drive the recurring revenues associated with the sale of
single-use disposable ODM probes which are used in the TrueVue
System and to complement these revenues with a new incremental
revenue stream to be derived from the Group's new non-invasive
technology.
Both the existing single-use ODM
probe and the new, non-invasive device will connect to the same,
new TrueVue monitor which was released onto the market in November
2023. Monitors are sold or, due to hospitals' often protracted
procurement times for capital items, may be loaned in order to
encourage faster adoption of the Group's technology.
Deltex Medical's customers
The principal users of Deltex
Medical's products are currently anaesthetists working in a
hospital's operating theatre and intensivists working in ICUs. This
customer profile will change as the Group's new non-invasive
technology is adopted by the market. In the UK the Group sells
directly to the NHS. In the USA the Group sells directly to a range
of hospital systems. The Group also sells through distributors in
more than 40 countries in the European Union, Asia and the
Americas.
Deltex Medical's objective
To see the adoption of Deltex
Medical's new TrueVue monitor, comprising both minimally invasive
and non-invasive technologies, as the standard of care in
haemodynamic monitoring for all patients from new-born to adult,
awake or anaesthetised, across all hospital settings
globally.
For further information please go
to www.deltexmedical.com